Floatz logo

(Z)-Endoxifen

Ductal Breast Carcinoma In Situ

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)UNKNOWNPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Ductal Breast Carcinoma In Situ cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
Sufentanyl
Zealand University Hospital
Phase 4BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB
Oxybutynin
Academic and Community Cancer Research United
Phase 3BB

View all 50 →

Same molecule, other indications

(Z)-Endoxifen is also rated in:

breast carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
breast cancerActive
CCC
Indicative · Phase 2
53 / 100
View asset →
lobular breast carcinoma in situActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →